



Pharmabiotics 2026

Conference & Partnering
Brussels, Belgium 3-5 February



Pharmabiotic
Research Institute

The Pharmabiotic Research Institute is delighted to invite you to join us for the 2026 edition of the Pharmabiotics Conference, the Microbiome **Conference of Development & Regulation (D&R)**, taking place in Brussels on February 3-5, 2026.

Now in its 10th edition, Pharmabiotics is one of **Europe's oldest and most established microbiome meetings**. Over more than a decade, it has earned trust by **centering development and regulation**, and by **turning real regulatory journeys into practical case studies that move the field forward**.

Four **D**'s, one **R**:

- **Development:** Translating microbiome science into real-world products.
- **Direction:** Offering **Regulatory** compass points in a space that still lacks official guidelines.
- **Dialogue:** A unique platform where researchers, developers, regulators, and industry share their journeys. The conference fosters peer-to-peer exchange while also opening direct dialogue with those writing, interpreting, and implementing the rules that will define the next chapter of microbiome innovation.
- **Disruption:** Showcasing how microbiome science is reshaping health, food systems, and sustainability.

Behind the conference stands the **Pharmabiotic Research Institute (PRI)**, Europe's Microbiome Regulatory Science Center. PRI is an independent non profit, recognized as a stakeholder with key EU institutions, and supported by the largest microbiome network in Europe.

What sets Pharmabiotics apart is its focus on regulatory case studies. Faced with guidelines that are limited, outdated, and not designed for a paradigm-shifting field like the microbiome, the conference creates a space where researchers and developers share how they have

navigated classification issues, engaged with regulators, and adapted their development pipelines.

Continuing its tradition of excellence, the 2026 programme will dive into the critical challenges and transformative opportunities shaping the future of microbiome science, clinical application, and innovation.

The programme is built around four core themes:

- **Microbiome-based biomarkers, testing, and diagnostics.**
- **Microbiome innovation within the One Health concept**, expanding applications beyond human health.
- **Regulatory assessment and developments** impacting microbiome research and innovation.
- **Advances in clinical data & emerging technologies** in microbiome research.

“

“The Pharmabiotics Conference has firmly established itself as the key rendezvous for microbiome development and regulation in Europe. It is where discovery becomes development, where regulatory journeys are shared as case studies, and where the future of microbiome-based solutions takes shape. For anyone committed to advancing the field, this is where you come to understand the next frontier, and help shape it.”— Eleni Tsompanidou, Head of Microbial Discovery and Development at Winclove Probiotics, and President of the Pharmabiotic Research Institute.

”

Secure your spot today: www.pharmabioticsevent.com

To highlight **PRI's European identity**, the 10th edition will take place in **Brussels**, the heart of Europe. This symbolic location underscores **PRI's commitment to shaping the microbiome field within the European context**, while fostering international dialogue and collaboration.



Pharmabiotics 2026
Conference & Partnering
Brussels, Belgium 3-5 February



**Pharmabiotic
Research Institute**

Pharmabiotics: the microbiome **Conference** of **D&R** (development and regulation)

Preliminary programme

Day 1 - February 3rd

Morning session (PRI Members Only)

10:00–12:30 | Yearly regulatory science roundup – Key updates and perspectives on the evolving regulatory landscape

12:30–13:30 | Networking Lunch – An opportunity to connect with fellow PRI members ahead of the main conference programme.

Afternoon | 14:00 | Conference kick-off

Session 1: Microbiome-based biomarkers; Microbiome testing and diagnostics

- Microbiome biomarkers in Europe: From expert consensus to regulatory implementation (**Dr. Julie Rodriguez, PRI**)
- Bacterial markers and immune checkpoint inhibitors for oncology treatment (**Dr. Lisa Derosa, Institut Gustave Roussy**)
- Managing chronic diseases through gut microbiome-derived biomarkers (**Dr. Etienne Formstecher, GMT Science**)
- International consensus on microbiome testing in clinical practice (**Dr. Gianluca Ianiro, Università Cattolica del Sacro Cuore, Rome**)
- Human stool reference material to measure the gut microbiome
- Non-invasive diagnostics and the power of the vaginal microbiome: gynecological care and reproductive health (**Dr. Marta Ciechońska, Salient Bio**)
- | **Sponsor slot** |

Q&A session - Panel discussion

Evening | Welcome apéritif & networking

Day 2 - February 4th

Morning | Session 2: Microbiome innovation within the One Health concept, expanding microbiome application beyond human health

- Beyond Earth: Microbiome research for space missions and planetary health (**Dr. Rodrigo Coutinho, European Space Agency**)
- Unexplored microbial diversity from food metagenomes
- Plant-soil microbiome intersections (**Dr. Marc Ongena, Liege University**)
- Gut microbes vs PFAS: A new frontier in microbiome-driven detoxification (**Dr. Anna E. Lindell, Cambiotics**)
- Biostimulant regulation and sustainable agriculture solutions (**Geoffroy Moulin, Staphyt**)
- Opportunities and challenges in developing microbial products for biocontrol and crop enhancement (**Dr. Angela Sessitsch**)
- Roadmap for the integration of gastrointestinal (GI) microbiomes (human and domesticated animal) into risk assessments under EFSA's remit (**Dr. F. Javier Moreno, Spanish National Research Council, CSIC**)

Afternoon | Session 3: Microbiome in regulatory assessment and regulatory developments impacting microbiome R&D

- EFSA's microbiome science initiative (**Dr. Konstantinos Paraskevopoulos, EFSA**)
- Integrating environmental microbiome data into EFSA risk assessment (**Dr. Frédéric Debode, Walloon Agricultural Research Centre**)
- SoHO Regulation and the Microbiome: What's at stake, and where we go next (**Dr. Céline Druart, PRI**)
- Implementing the SoHO Regulation: Technical guidance from HARMONIZE, EDQM & ECDC (**Dr. Lena Biehl, Fraunhofer Institute for Translational Medicine and Pharmacology Frankfurt University of Cologne, Köln**)
- New SoHO regulation: EDQM guide on tissues and cells (**Dr. Josbert Keller, Haaglanden Medical Center**)
- SoHO Regulation in Practice: Updates on Implementation, GDPR and Clinical Trials (**Stefaan Van der Spiegel, EC, DG Santé, Soho Head of Sector**)

2026 Featured session | Next Colony: Space.

How can space boost microbiome-based innovation, and how can microbiome innovations drive space exploration? Join experts Dr. Christian Roghi and Dr. Pierre Burguière for an exclusive discussion on the intersection of microbiome science and space research.

Evening | Dinner at Wolf Sharing Food Market, Brussels city centre.

Day 3 - February 5th

Session 4: Microbiome Innovation: Advances in Clinical Data & Emerging Technologies

- EXL01: A Novel single-strain live biotherapeutic for macrophages modulation - Early clinical data and mechanism of action revealed (**Benjamin Hadida, Exeliom Biosciences**)
- Precision microbiome medicines for immuno-oncology and inflammatory bowel disease (**Dr. Adam Wilkinson, Microbiotica**)
- Synbiotics and infant colic: Clinical trial results (**Professeur Yvan Vandenplas, UZ Brussel**)
- Harnessing GMO microbial strains to restore and support skin health (**Dr. Maria Jose Fabrega, Synflora**)
- Precision sampling of the gut microbiome: clinical data from Nimble Science's capsule technology (**Dr. Sabina Bruehlmann, Nimble Science CEO**)
- Microbiome science as a tool for safer therapeutics and food: where are we in 2025? (**David de Gruijl, Co-founder, Anto Biosciences**)
- Decoding Autism: Multi-Omics and AI insights into the gut-brain axis (**Dr. Jamie Morton, Gutz Analytics**)
- Cognitive and mood benefits of multistrain Probiotics in healthy older adults: Evidence from a randomized controlled trial (**Dr. Daniel Lamport, Associate Professor, School of Psychology & Clinical Language Sciences, University of Reading**)
- | Sponsor slot |

Poster Session and Awards

14:00 | Conference ends

Register now: Be part of the **10th Pharmabiotics Conference**, the **Conference of Development & Regulation** of the Microbiome. **February 3–5, 2026, Brussels, Belgium**

Join leaders from research, industry, and regulation for **three days dedicated to turning discovery into development** and **navigating regulatory pathways** in a field where frameworks remain limited and evolving.

Through **real-world case studies** and **cross-disciplinary dialogue**, the conference offers **practical insights you won't find elsewhere**, showing how regulatory journeys shape microbiome innovations across health, food, and sustainability.

Secure your place today: www.pharmabioticsevent.com

Contact us

Have questions about registration, sponsorship, or participation?

Reach out directly to our team:

- **Camille Bello** – camille@pharmabiotic.org
- **Céline Druart** – celine@pharmabiotic.org

Stay up to date: www.pharmabioticsevent.com

